Ignite Creation Date:
2024-05-05 @ 10:54 PM
Last Modification Date:
2024-10-26 @ 10:26 AM
Study NCT ID:
NCT01217229
Status:
COMPLETED
Last Update Posted:
2020-06-30
First Post:
2010-10-04
Brief Title:
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Sponsor:
Daiichi Sankyo
Organization:
Daiichi Sankyo
Study Overview
Official Title:
A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Status:
COMPLETED
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
PLX3397 is a selective inhibitor of Fms Kit and oncogenic Flt3 activityThe primary objective of this study is to evaluate the efficacy as measured by overall response rate of orally administered PLX3397 in patients with relapsed or refractory classical Hodgkin lymphoma HL Secondary objectives include safety the duration of response the disease control rate progression free survival and how the drug affects your body
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None